PROFESSOR G. M. REDDY's
CENTRE FOR PLANT MOLECULAR BIOLOGY
OSMANIA UNIVER SITY
HYDERABAD - 500 007, INDIA

CPMB Home Page

 

Dr. Rama Krishna Kancha

Assistant Professor, UGC – Faculty Recharge Programme (Biosciences)

Molecular Medicine and Therapeutics Laboratory (MMTL)

Centre for Plant Molecular Biology, Osmania University,  Hyderabad - 500 007, INDIA.

Dr. Rama Krishna Kancha obtained his M.Sc. in Biotechnology from the University of Calicut (Kerala, India) and Ph.D (in cancer biology) from the Technical University of Munich, Germany. Dr. Kancha performed post-doctoral work at the Technical University of Munich (Munich, Germany), University Medical Center Freiburg (Freiburg, Germany) and BioMed X Innovation Center (Technology Park, Heidelberg, Germany).

Publications:

1

Chuanjiang Yu1*, Kancha RK1*, and Duyster J. (2014) “Targeting oncoprotein stability overcomes drug resistance caused by FLT3 kinase domain mutations” PLoS ONE, 8 (7): e68394.      
1* - Equal first author contribution

2

Kancha RK, Bartosch N, and Duyster J. (2013) “Analysis of conformational determinants underlying HSP90-Kinase interactions” PLoS ONE, 8 (7): e68394.

*Recommended as an article of special significance by the F1000Prime

Citation: F1000Prime, 24 Jul 2013; DOI: 10.3410/f.718031098.793480405

3

Kancha RK, von Bubnoff N, Duyster J. (2013) “Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation” Cell Communication and Signaling, 11 (1): 39.

4

Van Os T.A.M., Kunst, P.W.A, Weegenaar, J., Reinten, R., van Noesel, J., Van der Ven, W.H., Kancha RK, Duyster J and C.J.M. van Noesel. (2013) “An activating germline R776H mutation in the Epidermal Growth Factor Receptor associates with lung cancer with squamous differentiation” Journal of Clinical Oncology, 31(10): e161-4.

5

Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J. (2011) “Irreversible ERBB2 inhibitors overcome lapatinib resistance generated by ERBB2 kinase domain mutations” PLoS ONE, 6(10): e26760.

6

Kancha RK, Peschel C, Duyster J (2011). “The EGFR-L861Q mutation increases intrinsic kinase activity without leading to enhanced sensitivity towards EGFR kinase inhibitors” Journal of Thoracic Oncology, 6(2): 387-92.

7

Heidel F, Lipka DB, Mirea FK, Mahboobi S, Grundler R, Kancha RK, Duyster J, Naumann M, Huber C, Böhmer FD, Fischer T. (2009) “Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412 in vitro” British Journal of Haematology, 144(6): 865-74.

8

Kancha RK, von Bubnoff N, Peschel C, Duyster J. (2009) “Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy” Clinical Cancer Research, 15(2): 460-467.

9

Kancha RK, von Bubnoff N, Miething C, Peschel C, Götze KS, Duyster J. (2008) “Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation” Haematologica, 93(11): 1718-22.

10

Kancha RK, Grundler R, Peschel C, Duyster J. (2007) “Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations” Experimental Hematology, 35(10): 1522-6.

11

von Bubnoff N, Gorantla SH, Kancha RK, Lordick F, Peschel C, Duyster J. (2005) “The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107” Leukemia, 19(9): 1670-1.

 

Further details:

Linkedin

http://de.linkedin.com/pub/dr-rama-krishna-kancha/b/4ab/657

ResearchGate

https://www.researchgate.net/profile/Rama_Krishna_Kancha/

GoogleScholar

http://scholar.google.com/citations?user=AcvodsYAAAAJ&hl=en

BiomedExperts

http://www.biomedexperts.com/Profile.bme/1738608/Rama_Krishna_Kancha

 
Contact Details
E Mail :  ramakancha@osmania.ac.in
Phone No. : +91-40-27098087 and +91-40-27682375

Fax No. : +91-40-27096170

 

 

                                                                               CPMB HOME